Peter Hoagland, MD
Advanced Heart Failure and Transplant Cardiology · San Diego, CANPI 1629059779
Payments from drug & device makers
Across 385 payments — averaging $628.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Accriva Diagnostics Inc.$170K
- Novartis$24K
- Boston Scientific$19K
- Amgen$14K
- Amarin Pharma, Inc.$6K
- Boehringer Ingelheim$3K
- plus $5K from 34 others
What the payments were for
- Consulting fees$4355%
- Speaking & faculty fees$2,89531%
- Food & beverage$5,95563%
- Education$1081%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PRADAXA$2,830
- FARXIGA$500
- CardioMEMS HF System$140
- Xience Sierra Coronary Stent System$131
- Vascepa$123
How this compares
$241,826 in reported general payments places this provider in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 278 | $394,719 |
| EntrestoSacubitril/Valsartan | 120 | $194,373 |
| XareltoRivaroxaban | 124 | $185,518 |
| JardianceEmpagliflozin | 73 | $97,507 |
| FarxigaDapagliflozin Propanediol | 72 | $89,902 |
| VascepaIcosapent Ethyl | 62 | $38,910 |
| Repatha SureclickEvolocumab | 33 | $37,091 |
| Repatha PushtronexEvolocumab | 19 | $22,451 |
| Praluent PenAlirocumab | 14 | $18,802 |
| NexlizetBempedoic Acid/Ezetimibe | 16 | $15,174 |
| Ezetimibe | 223 | $9,522 |
| Dofetilide | 18 | $7,948 |
| Valsartan | 200 | $7,387 |
| Atorvastatin Calcium | 409 | $4,394 |
| Rosuvastatin Calcium | 171 | $4,096 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $249 | $394,719278 claims |
| NovartisEntresto | $23,771 | $194,373120 claims |
| Johnson & JohnsonXarelto | $179 | $185,518124 claims |
| Boehringer IngelheimJardiance | $2,953 | $97,50773 claims |
| AstraZenecaFarxiga | $1,096 | $89,90272 claims |
| Esperion Therapeutics, Inc.Nexlizet | $108 | $15,17416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in San Diego
- Eric AdlerSan Diego$1.4M
- Marcus UreySan Diego$987K
- Hirsch MehtaSan Diego$845K
- Brian JaskiSan Diego$662K
- Jorge Silva EncisoSan Diego$580K
- Barry GreenbergSan Diego$322K
- Hao TranSan Diego$319K
- Ajay SrivastavaSan Diego$203K
- Burhan MohamedaliSan Diego$174K
- Justin ParizoSan Diego$104K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.